Exclusive: Biogen eyes a list of potential acquisitions; strong new evidence suggests a virus triggers MS

Biogen, desperate to reverse the turmoil surrounding Aduhelm, has a shopping list of potential acquisitions, STAT has learned. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        STAT+: With its Alzheimer's drug in turmoil, Biogen eyes a list of potential acquisitions By Damian Garde and Adam Feuerstein Steven Senn/AP Biogen, desperate to reverse the turmoil surrounding its controversial Alzheimer’s treatment, has a shopping list of potential acquisitions. Read More Strong new evidence suggests a virus triggers multiple sclerosis By Megan Molteni CDC Researchers have found strong evidence that infection with the Epstein-Barr virus, best known for causing mononucleosis, triggers MS. Read More With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer's treatment By Nicholas Florko Luca Bruno/AP With its proposal to restrict access to an Alzheimer's drug, Medicare joins a debate about addressing inequities in treatment for the disease Read More Sponsor content by Organon Ecosystem-wide approach to tackle women's health challenges in 2022 Global healthcare leaders will unite virtually for the annual JP Morgan Healthcare Conference to preview the latest health advances. It's time for women's health to own a bigger portion of this discussion and it will require an intentional ecosystem-wide effort to drive much needed change for every woman everywhere. Find out more about how we'll do that and the role we can all play. STAT+: In a battle over the future of U.S. health care, a question emerges: Is primary care scalable? By Casey Ross Adobe Startups, retail giants, and technology-first players like Amazon and Teladoc are all in a pitched battle for the future of primary care. Read More A cascade of Omicron-driven shortages puts U.S. hospitals in a bind By Eric Boodman and Isabella Cueto Justin Hamel for STAT The scarcity of Covid drugs is just one element in a cascade inundating hospitals from Boston to El Paso, from Florida to Washington state. Read More Supreme Court halts Covid-19 vaccine rule for U.S. businesses By Mark Sherman and Jessica Gresko — Associated Press Dana Verkouteren via AP At the same time, the court is allowing the administration to proceed with a vaccine mandate for most health care workers in the U.S. Read More STAT+: Telehealth companies are testing the waters with taking on more risk By Mohana Ravindranath Adobe Several telehealth companies are dipping into payment models that reward for keeping patients’ costs low and penalize for overspending. Read More STAT+: A new biotech startup looks to sidestep a key problem with CAR-T cancer therapies By Angus Chen Courtesy Fred Hutch/Robert Hood Biotech startup Affini-T Therapetuics aims to use engineered T-cell receptors, or TCRs, to target the source of cancerous cells. Read More Unvaccinated pregnant people are at higher risk for Covid complications and newborn deaths By Theresa Gaffney Charles Krupa/AP In a study from Scotland, unvaccinated pregnant people who get Covid-19 are at much higher risk for complications from the disease. Read More Listen: #JPM22 in review, Biogen's worsening fortunes, & the future of RNA drugs By Damian Garde and Meg Tirrell and Adam Feuerstein STAT health tech correspondent Katie Palmer joins us this episode to recap the J.P. Morgan Healthcare Conference. Read More Thursday, January 13, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser